Present and future molecular testing of lung carcinoma

Area of Science:

• Oncology
• Genomics
• Molecular Diagnostics

Background:

• Targeted therapies have revolutionized lung carcinoma treatment.
• Identifying predictors of response to these therapies is crucial for patient outcomes.
• Standardized molecular testing has become essential in clinical practice.

Purpose of the Study:

• To review the current practices in molecular testing for lung carcinoma.
• To discuss the standardization of testing for specific genomic alterations.
• To provide a brief overview of future molecular testing methods.

Main Methods:

• Literature review of studies on molecular testing in lung cancer.
• Analysis of published guidelines for molecular testing.
• Synthesis of current evidence on targeted therapy response predictors.

Main Results:

• Molecular testing for EGFR mutations and ALK rearrangements in lung adenocarcinoma is standardized.
• Targetable drugs demonstrate superior efficacy and progression-free survival in patients with specific genotypes.
• The range of targetable genomic alterations in lung carcinoma is expanding beyond established markers.

Conclusions:

• Molecular testing is the standard of care for predicting response to targeted lung cancer therapies.
• Established tests for EGFR and ALK mutations are widely implemented.
• Ongoing research is expanding the landscape of targetable biomarkers for lung carcinoma.